info@ribogenyx.com
REWRITING THE RULES OF AGEING AT THE RIBOSOME

EXCELLENCE in
translational fidelity

Developing first-in-class therapeutic enhancers to revolutionize medical interventions

Our Purpose

Our Mission

Developing first-in-class translational fidelity enhancers to revolutionize therapeutic interventions targeting mRNA translation processes. At Ribogenyx, we're dedicated to unlocking new frontiers in precision medicine through innovative technologies that enhance translational fidelity.

100% Novel Technology
10+ Research Papers
Leadership

Our Founders

Angelos Glynos

Angelos Glynos

PhD

Co-Founder

Completing his PhD and postdoc in mitochondrial genomics in the lab of Prof. Patrick Chinnery at the University of Cambridge, Angelos published the projects he led at Cell and Science Advances before joining Altos Labs. There, he applied his expertise in generating novel datasets aimed at discovering and validating novel drug targets.

"I see founding RibogenyX as a once-in-a-lifetime opportunity to apply my expertise on something truly unique. A pursuit with the potential to change the way we think about therapeutic interventions targeting the process of mRNA translation."
Maxime Derisbourg

Maxime Derisbourg

PhD

Co-Founder

With over a decade of combined academic and industry experience in age-related diseases, Maxime is driven by a deep passion for fundamental biology and the mechanisms of stress resilience mediated by mRNA translation. With a background in neurobiology and the genetics of aging, he is committed to improving the lives of individuals affected by age-related conditions.

"Founding RibogenyX fulfills my lifelong dream, to make a meaningful and immediate impact on patients' lives by pioneering a new paradigm: targeting ribosomes to enhance cellular resilience"

Ready to improve healthspan?

Join us in October 2025 in pioneering translational fidelity technology